TO
TON.F Toho Holdings Co. Ltd
- Market cap
- EUR 1.44B
- P/E
- 17.5x
- P/B
- 0.90x
- ROE
- 3.5%
- Dividend yield
- 4.61%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is TON.F undervalued?
Graham numberTON.F trades 16.3% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Toho Holdings Co. Ltd fundamental analysis
No fundamental analysis for Toho Holdings Co. Ltd yet.
Toho Holdings Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Toho Holdings Co. Ltd
Toho Holdings Co., Ltd., together with its subsidiaries, engages in the wholesale distribution of pharmaceutical products in Japan. It operates in four segments: Pharmaceutical Wholesaling Business, Dispensing Pharmacy Business, Pharmaceutical Manufacturing and Sales Business, and Other Peripheral Businesses. The company distributes pharmaceuticals, narcotics, reagents, medical equipment and devices, medical materials, and over-the-counter products to hospitals, clinics, and…
Full company profileToho Holdings Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Toho Holdings Co. Ltd annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.23T | 1.21T | 1.22T | 1.26T | 1.21T | 1.27T | 1.39T | 1.48T | 1.52T | 1.55T | 1.59T |
| Gross Profit | 110B | 114B | 112B | 115B | 99.4B | 109B | 114B | 119B | 122B | 122B | 118B |
| Operating Income | 14.3B | 19.0B | 15.8B | 17.6B | 4.31B | 12.5B | 16.4B | 19.3B | 18.8B | 16.3B | 9.88B |
| EBITDA | - | 29.7B | 27.4B | 30.1B | 17.1B | 27.1B | 26.9B | 37.4B | 34.2B | 32.4B | 18.3B |
| Net Income | 14.2B | 14.4B | 13.9B | 16.2B | 4.99B | 13.4B | 13.6B | 20.7B | 19.8B | 17.3B | 9.42B |
| EPS | 207 | 210 | 203 | 230 | 71 | 190 | 204 | 329 | 317 | 268 | 146 |
| Balance Sheet | |||||||||||
| Total Assets | 599B | 647B | 664B | 671B | 683B | 702B | 715B | 773B | 723B | 741B | 773B |
| Total Liabilities | 411B | 439B | 450B | 440B | 446B | 461B | 472B | 524B | 466B | 469B | 507B |
| Shareholders' Equity | 188B | 208B | 214B | 231B | 237B | 241B | 243B | 249B | 257B | 271B | 266B |
| Cash & Short-term Investments | 32.0B | 67.9B | 79.6B | 84.2B | 93.1B | 94.3B | 86.2B | 133B | 86.5B | 87.4B | 102B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 16.1B | 52.0B | 13.4B | 10.8B | 8.77B | 16.3B | -9.00M | 59.9B | -26.7B | 19.2B | - |
| Capital Expenditure | 7.16B | 8.46B | 2.80B | 11.9B | 4.14B | 3.62B | 2.52B | 3.78B | 5.76B | 9.51B | 0.00 |
| Free Cash Flow | - | 43.0B | 9.63B | -3.06B | 3.04B | 12.1B | -2.53B | 56.2B | -32.4B | 9.73B | - |
| Ratios | |||||||||||
| ROE | 7.6% | 6.9% | 6.5% | 7.0% | 2.1% | 5.5% | 5.6% | 8.3% | 7.7% | 6.4% | 3.5% |
| ROA | 2.4% | 2.2% | 2.1% | 2.4% | 0.7% | 1.9% | 1.9% | 2.7% | 2.7% | 2.3% | 1.2% |
| Net Profit Margin | 1.2% | 1.2% | 1.1% | 1.3% | 0.4% | 1.1% | 1.0% | 1.4% | 1.3% | 1.1% | 0.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Toho Holdings Co. Ltd dividends
- Dividend yield
- 4.61%
- Forward dividend
- 1.02 EUR
- Payout ratio
- 31.4%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 5.45B | 84 | 31.4% |
| 2025 | JPY 3.02B | 48 | 15.2% |
| 2024 | JPY 2.24B | 36 | 10.8% |
| 2023 | JPY 2.19B | 33 | 16.0% |
| 2022 | JPY 2.12B | 30 | 15.8% |
| 2021 | JPY 2.47B | 35 | 49.5% |
| 2020 | EUR 2.43B | 34 | 15.0% |
| 2019 | EUR 2.03B | 30 | 14.6% |
| 2018 | EUR 2.06B | 30 | 14.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Toho Holdings Co. Ltd
- Insiders 11.76%
- Institutions 37.89%
- Public & others 50.35%
- Shares outstanding 64.7M
- Free float 43.4M
Toho Holdings Co. Ltd company profile
- Company name
- Toho Holdings Co. Ltd
- Ticker
- TON.F
- ISIN
- JP3602600003
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 7,675
- Fiscal year end
- March
- Address
- Tokyo Midtown Yaesu, Yaesu Central Tower, Chuo, Japan, 104-0028
- Phone
- 81 3 6838 2800
- Website
- tohohd.co.jp
About Toho Holdings Co. Ltd
Toho Holdings Co., Ltd., together with its subsidiaries, engages in the wholesale distribution of pharmaceutical products in Japan. It operates in four segments: Pharmaceutical Wholesaling Business, Dispensing Pharmacy Business, Pharmaceutical Manufacturing and Sales Business, and Other Peripheral Businesses. The company distributes pharmaceuticals, narcotics, reagents, medical equipment and devices, medical materials, and over-the-counter products to hospitals, clinics, and dispensing pharmacies. It also provides customer support systems for patients and medical institutions comprising Future ENIF, an information terminal for pharmaceutical ordering; LXMATE HeLios Cloud, a medical care appointment system; and MIZAR, a centralized administration system of pharmacy operations, as well as L1MON, a patient home delivery service for specialty products. In addition, the company engages in the management of the dispensing pharmacies and health insurance dispensing pharmacies; provision of support home medical care and data processing services; and real estate agency business. Further, it provides generic and injection drugs on consignment; contract manufacturing of ampoule and vial formulations; and contract testing for pharmaceutical quality control and stability testing. Additionally, the company engages in site management organization; planning and sale of information processing equipment; software development and sales; corporate and medical management and consulting; internet business related to pharmaceuticals; general motor truck transportation; cashless payment and factoring; remote detailing; and manufacture and sale of hygienic materials. The company was formerly known as Toho Pharmaceutical Co., Ltd. and changed its name to Toho Holdings Co., Ltd. in April 2009. Toho Holdings Co., Ltd. was incorporated in 1948 and is headquartered in Chuo, Japan.
Toho Holdings Co. Ltd management
10- Mr. Hiromi EdahiroPresident, CEO & Representative Director · born 1952
- Yasuo SakaeSenior Managing Executive Officer & CFO
- Mr. Akira UmadaSenior Executive MD, COO, Head of Sales & Director · born 1965
- Mr. Takeo MatsutaniSenior Managing Executive Officer, CGO & Director · born 1966
- Mr. Kengo OgawaCorporate Officer · born 1967
- Mr. Makoto KawamuraSenior Managing Executive Officer
- Mr. Shuzo KonoSenior Managing Executive Officer & Director · born 1978
- Aiko NoshiroCorporate Officer
- Shigeki NakataSenior Executive Officer
- Osamu KomaiCorporate Officer